156 related articles for article (PubMed ID: 30519347)
1. Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Nowicki M; Brązert J; Januchowski R
J Cancer; 2018; 9(23):4413-4421. PubMed ID: 30519347
[No Abstract] [Full Text] [Related]
2. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Andrzejewska M; Rusek D; Sobkowski M; Kędzia W; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257426
[TBL] [Abstract][Full Text] [Related]
3. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Nowacka M; Kaźmierczak D; Andrzejewska M; Rusek D; Brązert M; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583585
[TBL] [Abstract][Full Text] [Related]
4. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.
Świerczewska M; Klejewski A; Wojtowicz K; Brązert M; Iżycki D; Nowicki M; Zabel M; Januchowski R
Molecules; 2017 Oct; 22(10):. PubMed ID: 29027969
[TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
6. The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines.
Wojtowicz K; Świerczewska M; Nowicki M; Januchowski R
Adv Med Sci; 2023 Sep; 68(2):379-385. PubMed ID: 37806183
[TBL] [Abstract][Full Text] [Related]
7. PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.
Świerczewska M; Sterzyńska K; Wojtowicz K; Kaźmierczak D; Iżycki D; Nowicki M; Zabel M; Januchowski R
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027318
[No Abstract] [Full Text] [Related]
8. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
[TBL] [Abstract][Full Text] [Related]
9. Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell Lines.
Januchowski R; Świerczewska M; Sterzyńska K; Wojtowicz K; Nowicki M; Zabel M
J Cancer; 2016; 7(10):1295-310. PubMed ID: 27390605
[TBL] [Abstract][Full Text] [Related]
10. The significance of lumican expression in ovarian cancer drug-resistant cell lines.
Klejewski A; Sterzyńska K; Wojtowicz K; Świerczewska M; Partyka M; Brązert M; Nowicki M; Zabel M; Januchowski R
Oncotarget; 2017 Sep; 8(43):74466-74478. PubMed ID: 29088800
[TBL] [Abstract][Full Text] [Related]
11. New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.
Klejewski A; Świerczewska M; Zaorska K; Brązert M; Nowicki M; Zabel M; Januchowski R
Anticancer Res; 2017 Apr; 37(4):1625-1636. PubMed ID: 28373423
[TBL] [Abstract][Full Text] [Related]
12. Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines.
Sterzyńska K; Kaźmierczak D; Klejewski A; Świerczewska M; Wojtowicz K; Nowacka M; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412536
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.
Wojtowicz K; Januchowski R; Nowicki M; Zabel M
Biomed Pharmacother; 2015 Aug; 74():49-56. PubMed ID: 26349962
[TBL] [Abstract][Full Text] [Related]
14. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
Januchowski R; Zawierucha P; Ruciński M; Zabel M
Oncol Rep; 2014 Nov; 32(5):1981-90. PubMed ID: 25199881
[TBL] [Abstract][Full Text] [Related]
15. New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines.
Świerczewska M; Klejewski A; Brązert M; Kaźmierczak D; Iżycki D; Nowicki M; Zabel M; Januchowski R
Molecules; 2018 Apr; 23(4):. PubMed ID: 29649113
[TBL] [Abstract][Full Text] [Related]
16. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
[TBL] [Abstract][Full Text] [Related]
17. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sterzyſska K; Sosiſska P; Andrzejewska M; Zawierucha P; Nowicki M; Zabel M
Int J Biochem Cell Biol; 2016 Sep; 78():248-259. PubMed ID: 27443528
[TBL] [Abstract][Full Text] [Related]
20. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
